1. What terms should AMS consider interchangeable with ‘bioengineering’? (Sec. 291(1))

**Context:** The disclosure standard would be a mechanism to inform consumers about their food. AMS is considering the advantages and disadvantages of allowing the use of other terms to provide for disclosure.

Any and all instances of genetic engineering should be, in my opinion, considered bioengineering and disclosed to the public, including “traditional” methods of producing genetically modified organisms (GMOs), the newer gene editing techniques such as CRISPR and others, and any other technique that may potentially be used to alter the genetic material of living beings.

2. Which breeding techniques should AMS consider as conventional breeding? (Sec. 291(1)(B))

**Context:** AMS is considering what would be defined as modifications that could otherwise be obtained through conventional breeding because these modifications would be exempt from mandatory disclosure.

Conventional breeding should only include traditional breeding methods such as selecting varieties resulting from sexual reproduction between closely related species.

3. Which modifications should AMS consider to be found in nature? (Sec. 291(1)(B))

**Context:** AMS is considering what would be defined as modifications that could otherwise be found in nature because these modifications would be exempt from mandatory disclosure.

Any modification of genetic material using modern biotechnology, whether GMOs, gene editing or others should NOT be considered to be found in nature. Even if the traits introduced are found in nature, they are introduced via artificial means into the genome of the target organisms in ways that do not occur in nature and should therefore NOT be considered to be otherwise found in nature.

4. Will AMS require disclosure for food that contains highly refined products, such as oils or sugars derived from bioengineered crops? (Sec. 291(1)(A))

**Context:** Many processed foods may contain ingredients derived from bioengineered crops, such as highly refined oils or sugars that contain undetectable levels of bioengineered genetic material such that they are indistinguishable from their non-engineered counterparts. AMS is considering whether to require disclosure for foods containing those derived ingredients that may be undetectable as bioengineered.

Yes, AMS should also require disclosure of foods containing highly refined ingredients, even if the levels of bioengineered genetic material are undetectable. First, undetectable does not mean not present (current test could be inadequate). In addition, the impacts of bioengineering go beyond just the potential effects on consumers. A consumer may not want to purchase a
bioengineered product for many reasons and concerns (including but not limited to environmental effects, the ethics or lack thereof of patenting life, and many more). Although beyond the scope of the present regulation, I think disclosure should apply to any and all types of products, including but not limited to drugs, dietary supplements, cosmetics, clothing, etc.

6. Meat, poultry, and egg products are only subject to a bioengineered disclosure if the most predominant ingredient, or the second most predominant ingredient if the first is broth, stock, water, or similar solution, is subject to the labeling requirements under the Federal Food, Drug, and Cosmetic Act. How will AMS determine the predominance of ingredients? (Sec. 292(c))

**Context:** AMS is considering how to evaluate predominance to determine how the Law will apply to multi-ingredient food products.

If bioengineered products are present in any amount, they should be disclosed, regardless of whether they are first, second or last. The vast majority of people want to know, so don’t hide behind technicalities.

7. How should AMS craft language in the regulations acknowledging that the Law prohibits animal products from being considered bioengineered solely because the animal consumed feed products from, containing, or consisting of a bioengineered substance? (Sec. 293(b)(2)(A))

**Context:** AMS is considering regulatory language similar to the wording in the Law and if the Agency should provide clarity that food derived from any animal, including invertebrates such as crickets or bee products, would not require disclosure as a bioengineered food solely because their nutrition came from food with bioengineered ingredients.

If animals were fed bioengineered products, the public has the right to know. You may not want to label the animal product as bioengineered, but it should be disclosed that the animals were fed (or otherwise treated with) bioengineered products.

8. What is the amount of a bioengineered substance present in a food that should make it be considered bioengineered? (Sec. 293(b)(2)(B))

**Context:** The Law authorizes the Secretary to determine the amount of a bioengineered substance present in food in order for the food to be disclosed as a bioengineered food. The amounts of a bioengineered substance that may be present in food in order for the food to be a bioengineered food might be determined in a variety of ways: if a bioengineered substance is near the top of the list of ingredients, by determining the percentage of bioengineered ingredients in a food product, or by listing any ingredient that was produced through bioengineering, among others. AMS is considering how to determine the amount of bioengineered food or ingredient needed for a product to require a bioengineered disclosure, as well as the advantages and disadvantages of various methods.

Any amount, no matter how small, should be disclosed.
9. Should AMS consider more than one disclosure category? (Sec. 293(b)(2)(D))

**Context:** AMS is considering if it should develop various categories for disclosure and if it should differentiate between those products that a) are bioengineered, b) contain ingredients that are bioengineered, or c) contain ingredients derived from bioengineered crops or animals. Additionally, AMS is considering the creation of a set of disclosures for a category of bioengineered foods for those products that, due to changes in sourcing, include bioengineered ingredients for part of the year, and non-bioengineered ingredients for other parts of the year. AMS is considering the advantages and disadvantages, based on cost, clarity, and other factors, of using a single disclosure category or multiple disclosure categories.

Yes, if it leads to a fuller disclosure of how the product was made and what type of ingredients were used.

10. What other factors or conditions should AMS consider under which a food is considered a bioengineered food? (Sec. 293(b)(2)(C))

**Context:** AMS must develop a process to help stakeholders determine whether a food is subject to bioengineered disclosure. AMS anticipates the process would include considering factors such as: whether a food contains a substance that has been modified using recombinant in vitro DNA techniques (Sec. 291(1)(A)), whether the modification could not be obtained through conventional breeding or found in nature (Sec. 291(1)(B); Question 2 and 3), and whether a food requires disclosure based on the predominance of ingredients (Sec. 292(c); Question 6), among others. The outcomes of these determination requests might be publically posted on a Web site. The process to implement Sec. 293(b)(2)(C) is not intended to be an investigation or enforcement process (see Questions 26-29); instead, the implementation would likely be framed for manufacturers or developers of bioengineered food or ingredients who have a question on whether their food is subject to disclosure. AMS is considering the factors to be considered, the way to inform the public about the outcome of the requests, and ideas regarding the process to be used to make the determination.

This sounds like a trick question—trying to find some sort of loophole to disclose as little information as possible. I urge you to be transparent and disclose all instances of biotechnological modifications. People have a right to know and choose what food and products to buy.

11. Could AMS consider whether a type of food is considered a bioengineered food under the determination process? (Sec. 293(b)(2)(C))

**Context:** AMS is considering if it could exclude certain food types such as medical food and dietary supplements, among others from requiring disclosure as bioengineered.

No types of food should be excluded. People have a right to know. Disclosure should extend to all products beyond food, rather than trying to exclude certain food products.
13. If a manufacturer chooses to use a symbol to disclose a bioengineered food, what symbol should AMS require for disclosure? (Sec. 293(b)(2)(D))

**Context:** AMS needs to ensure that the symbol designed for the bioengineered disclosure is not disparaging toward bioengineering. As with the text disclosure, AMS must develop criteria for placement of the symbol to ensure consumers can readily locate the symbol, the symbol is scalable for different sized packages, and the symbol is a meaningful representation of bioengineered foods. AMS is considering what the symbol should look like and guidance on its use.

You could use the letter GE or GMO circled, or a strand of DNA and a test tube.

14. If a manufacturer chooses to use an electronic or digital link to disclose a bioengineered food, what requirements should AMS implement for an electronic or digital link disclosure? (Sec. 293(b)(2)(D))

**Context:** See Questions 23-25.

An electronic or digital link should only be allowed for additional information, but the basic information should be stated plain and clear in the product.

15. Should AMS specify in the regulations the type of electronic or digital disclosure manufacturers, e.g. QR code, can use to disclose bioengineered food? What steps should AMS take if an electronic or digital disclosure method becomes obsolete? (Sec. 293(b)(2)(D))

**Context:** AMS recognizes that disclosure technologies may quickly surpass regulations. AMS is considering what terms will ensure the regulations keep pace with technological changes and how AMS can notify stakeholders about changes in technology as they occur. AMS is also considering what the most appropriate electronic or digital disclosure technologies are currently and how to deal with obsolete technologies.

I don’t think it’s necessary to specify exactly what type of technology should be use; however electronic or digital disclosure should NOT be the only or main way the information is disclosed. The basic information should be provided plain and simple directly on the product because not everybody has access to technology, especially at the point of purchase. Electronic or digital means should only be used to provide supplemental information.

18. What are the reasonable disclosure options AMS should provide for food contained in very small or small packages? (Sec. 293(b)(2)(E))

**Context:** AMS is considering the disclosure standards for very small or small packages. FDA regulates nutrition labeling on very small or small packages differently. For example:

a. Could disclosure requirements for very small packages be met by providing an address or phone number where consumers could obtain the information?
b. Could disclosure requirements for small packages be met by providing abbreviated text disclosure or a Web site address where consumers could obtain disclosure information?

I think abbreviated text disclosure and a web site address and/or telephone number could be a reasonable compromise.

19. How should AMS define small food manufacturers? (Sec. 293(b)(2)(F))

**Context:** AMS is considering using regulatory language similar to that of other Federal government agencies that already define small businesses. For example:

a. FSIS considers small businesses to be those with 500 or fewer employees and that produces 100,000 pounds or less of annual production of a single product, including single forms of meat such as sausage, bulk, patties, links, consumer product, etc., when determining exemptions from nutrition facts labeling (9 CFR 317.400 (a)(1)(ii)).

b. FDA has several small business definitions with respect to food labeling rules, such as: i) retailers with total annual gross sales of $500,000 or less, 21 CFR 101.9(j)(1) and (18); ii) food and dietary retailers with annual gross sales of foods or dietary supplement products of $50,000 or less, 21 CFR 101.9(j)(1) and 101.36(h)(1); and iii) businesses that employ fewer than 100 full-time workers that produce a product that sells fewer than 100,000 units throughout the United States in a 12-month period, 21 CFR 101.9(j)(18) and 101.36(h)(2).

AMS is considering the advantages or disadvantages of these definitions of small food manufacturers for the bioengineered food disclosure regulations.

Regardless of how you define small food manufacturers, I think all food should disclose the presence of bioengineered ingredients.

25. How should AMS ensure that an electronic or digital disclosure can be easily and effectively scanned or read by a device? (Sec. 293(d)(5))

**Context:** AMS is aware that electronic or digital disclosures need to be effective, that requirements will vary for each specific type of electronic or digital disclosure, and that the technology for electronic or digital disclosure may change faster than AMS will be able to update its regulations. AMS is determining how to address these issues given the variety of electronic or digital disclosures currently available in the marketplace, along with the specifications for these disclosures to be used effectively in a retail setting.

The information should be available without the need of a digital or other technologies. Not everybody has access to these technologies, or may not be able to access them while shopping. Electronic or digital disclosures should be provided IN ADDITION to readily accessible information at the point of sale.

30. What should the requirements for imports into the United States of products covered by the Law/regulation be? (Sec. 294(a))
Context: AMS is considering how the disclosure requirements should be applied to imported products

Requirements should be as or more stringent as those for domestic products.

Thank you in advance for your consideration.

Gabriela Munoz
Dobbs Ferry, NY
Consumer.